Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10522329 | 0.83 | ALDH1A1 (0.46) | HTR2CCD44CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL25121118 | 0.79 | CD44 (0.35) | HPGDLMNAHTR2CCD44CYP1A2 | |
| SCHEMBL14547572 | 0.79 | HTR2C (0.32) | HTR2CCD44CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL9776180 | 0.78 | CNR1 (0.32) | HPGDHTR2CCD44CYP1A2CYP2A6 | |
| SCHEMBL7267859 | 0.77 | MAP3K14 (0.34) | HTR2CCD44CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL7693244 | 0.77 | HTR2C (0.33) | HTR2CCD44CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL423294 | 0.77 | ADORA2A (0.35) | HTR2CCD44CYP1A2CYP2A6CA1 | |
| SCHEMBL21009663 | 0.77 | MAP3K14 (0.34) | HTR2CCD44CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL4235163 | 0.76 | ALDH1A1 (0.33) | HTR2CALDH1A1 | |
| SCHEMBL9058839 | 0.76 | HTR2C (0.30) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | HPGD 919/4885LMNA 3670/4885HTR2C 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.